Publication: Partial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer
0
0
Issued Date
2022
Resource Type
Language
eng
File Type
application/pdf
ISSN
20726643
Rights Holder(s)
Scopus
Bibliographic Citation
Journal of Engineering Science and Technology. Vol 17, No.5 (2022), p.3424-3432
Suggested Citation
Sahasakul Y., Angkhasirisap W., Lam-Ubol A., Aursalung A., Sano D., Takada K., Trachootham D. Partial Substitution of Glucose with Xylitol Prolongs Survival and Suppresses Cell Proliferation and Glycolysis of Mice Bearing Orthotopic Xenograft of Oral Cancer. Journal of Engineering Science and Technology. Vol 17, No.5 (2022), p.3424-3432. doi:10.3390/nu14102023 Retrieved from: https://hdl.handle.net/20.500.14740/9662
Abstract
Many types of cancer have metabolic alterations with increased glycolysis. Identification of alternative sweeteners that do not fuel cancer is a novel approach to cancer control. The present study aimed to investigate the effects of xylitol on tumor growth and survival of mice bearing orthotopic xenograft of tongue cancers. The results showed that partial substitution of glucose with xylitol (glucose 0.35 g plus xylitol 2.06 g/kg body weight) non-significantly reduced tumor volume, and significantly prolonged the median survival time from 19 days in the control to 30.5 days in the xylitol group. Immunohistochemical data of the tongue tissue shows significantly lower intense-to-mild staining ratios of the proliferation marker Ki-67 in the xylitol than those of the control group (p = 0.04). Furthermore, the xylitol substitution significantly reduced the expression of the rate-limiting glycolytic enzyme, phosphofructokinase-1 (PFK-1) (p = 0.03), and showed a non-significant inhibition of PFK activity. In summary, partial substitution of glucose with xylitol at the equivalent dose to human household use of 10 g/day slows down tumor proliferation and prolongs survival of mice bearing an orthotopic oral cancer xenograft, possibly through glycolytic inhibition, with minimal adverse events. The insight warrants clinical studies to confirm xylitol as a candidate sweetener in food products for cancer survivors. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.